Search
Oxybuprocaine
go.drugbank.com/drugs/DB00892ApprovedInvestigationalOxybuprocaine binds to sodium channels and reversibly stabilizes the neuronal membrane which decreases its permeability to sodium ions.
Cisapride
go.drugbank.com/drugs/DB00604ApprovedWithdrawnThe FDA issued a warning letter regarding this risk to health care professionals and patients. … In many countries (including Canada) cisapride has been either withdrawn or has had its indications limited due to reports about long QT syndrome due to cisapride, which predisposes to arrhythmias.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor AgonistsTapentadol
go.drugbank.com/drugs/DB06204ApprovedInvestigationalIt is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. … The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeIloperidone
go.drugbank.com/drugs/DB04946ApprovedInvestigational[A3024] It is considered to be a second-generation antipsychotic drug [A263552] with multiple receptor binding profile, although it shows high affinity towards 5-HT<sub>2A</sub> and dopamine D2 receptors … Iloperidone is a benzisoxazole [A263557] and an atypical antipsychotic agent that was first approved by the FDA on May 6, 2009.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Adrenergic alpha-1 Receptor AntagonistsDesvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigationalAlthough the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. … [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeProducts: CAPSULAS DE LIBERACIÓN PROLONGADA, FAPRIS® 100MG TABLETAS DE LIBERACION PROLONGADASerotonin Receptors
go.drugbank.com/bio_entities/BE0004862TargetHumansReceptor for lasmiditan, a drug for the treatment of acute migraine (PubMed:34239069). … G protein-coupled receptor for 5-hydroxytryptamine (serotonin) (PubMed:10452531, PubMed:1565658, PubMed:1652050, PubMed:33762731).
Polypeptides: 5-hydroxytryptamine receptor 1A, 5-hydroxytryptamine receptor 1BSynonyms: Serotonin receptor 1A, Serotonin receptor 1BDiethylstilbestrol
go.drugbank.com/drugs/DB00255ApprovedWithdrawnAccording to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), diethylstilbestrol has been listed as a known carcinogen. … (Merck, 11th ed) The FDA withdrew its approval for the use of all oral and parenteral drug products containing 25 milligrams or more of diethylstilbestrol per unit dose.[L43942]
Categories: Sex Hormones and Modulators of the Genital SystemSynonyms: (E)-3,4-bis(4-hydroxyphenyl)-3-hexene, α,α'-diethyl-(E)-4,4'-stilbenediolHydroxyamphetamine
go.drugbank.com/drugs/DB09352Approvedstinging in the eyes. … The main use of hydroxyamphetamines as eye drops is the diagnosis of Horner's syndrome which is characterized by nerve lesions.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeEfonidipine
go.drugbank.com/drugs/DB09235InvestigationalThe drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.
Cilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalBlocking the interaction between the receptor-binding domain (RBD) of the S1 subunit and ACE2 inhibits viral host cell entry; animal studies indicate that antibodies capable of blocking this interaction … may be exposed to the virus.